Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
7 studies found for:    7526212 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
Condition: Proliferative Diabetic Retinopathy
Intervention: Drug: Aflibercept
2 Recruiting Pro-permeability and Pro-fibrosis Factors in the Aqueous of Patients With Retinal Diseases
Conditions: Macular Edema;   Fibrosis of the Retina
Interventions: Drug: Ozurdex;   Procedure: Surgery;   Procedure: Anterior Chamber (AC) Tap
3 Active, not recruiting Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab
Condition: Macular Degeneration
Intervention: Drug: 0.5mg ranibizumab
4 Completed Fractalkine, a CX3C Chemokine, Act as a Mediator of Ocular Angiogenesis
Conditions: Proliferative Diabetic Retinopathy;   Angiogenesis
5 Completed Ranibizumab Injections to Treat Macular Telangiectasia Without New Blood Vessel Growth
Condition: Macular Telangiectasia
Intervention: Drug: Ranibizumab
6 Completed Ranibizumab Injections to Treat Macular Telangiectasia With New Blood Vessel Growth
Condition: Neovascularization
Intervention: Drug: Ranibizumab
7 Completed
Has Results
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
Condition: Branch Retinal Vein Occlusion
Intervention: Drug: pegaptanib sodium (Macugen)

Indicates status has not been verified in more than two years